EI
SPRY icon

EAM Investors’s ARS Pharmaceuticals SPRY Stock Holding History

EAM Investors’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-261,649
Closed -$3.79M – 346
2024
Q3 		$3.79M Buy
+261,649
New +$3.11M 0.57% 92
2023
Q2 		– Sell
-62,798
Closed -$409K – 359
2023
Q1 		$409K Sell
62,798
-61,975
-50% -$476K 0.08% 242
2022
Q4 		$1.06M Buy
+124,773
New +$810K 0.22% 217

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

EAM Investors's SPRY Position: Q4 2024 in Review

EAM Investors sold out of ARS Pharmaceuticals (SPRY) in Q4 2024, closing a stake of 261,649 shares — an estimated $3.79M sold.

EAM Investors first reported a position in SPRY in Q4 2022 and held it in 3 quarters. The position peaked at $3.79M in Q3 2024. 165 funds tracked by Wall St. Rank hold SPRY as of Q4 2024.

  • EAM Investors reported no remaining ARS Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • EAM Investors sold 261,649 ARS Pharmaceuticals shares in Q4 2024, an estimated $3.79M.
  • EAM Investors first reported a position in ARS Pharmaceuticals in Q4 2022 and held it in 3 quarters.
  • EAM Investors's ARS Pharmaceuticals position peaked at $3.79M in Q3 2024.
  • 165 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q4 2024.

Based on EAM Investors's 13F filing for Q4 2024, filed 13 Feb 2025.